Scientific Breakthrough
Our team discovered that immune cells possess "VIP access" to actively traverse biological barriers, even dead skin, that block passive drug diffusion.
Non-invasive trans-barrier delivery
Turning Barriers
Into Gateways
OTO Biotech builds a proprietary immune-mediated drug delivery platform featuring non-invasive administration, active barrier-crossing transport, and targeted delivery to minimize systemic exposure and expand across multiple modalities and indications.
Platform
The Immune Trojan
Engineering Innovation
We developed proprietary liposomes that "hitchhike" on these immune cells by mimicking the body's natural C3b complement tagging process.
Versatile Platform
Our platform is compatible with a broad range of payloads, including antibiotics, proteins, and vaccines. It enables non-invasive localized delivery across multiple anatomical sites and diverse clinical indications.
Pipeline
Program Highlight
OTO - 101 for Acute Otitis Media
Solving the #1 Cause of Pediatric Antibiotic Overuse
acute otitis media cases are recorded in the U.S. each year, with 11.5 million occurring in children under 5.
Tong et al., BMC Health Serv. Res. 18(1) (2018)
of antibiotic prescriptions written for children in the United States are driven by acute otitis media.
Frost et al., J. Pediatr. 240, 221-227.e9 (2022)
is spent annually treating otitis media in children under 5 across the United States alone.
Lin et al., Front. Public Health 14, 1694807 (2026)
Competitive Landscape
Oral Antibiotics
Ear Drop
OTO-101
Administration
Repeated systemic dosing
Local, but limited by intact barrier
Non-invasive local administration
Transport Mechanism
Passive systemic circulation
Primarily passive diffusion
Active immune-cell-mediated transport
Systemtic Side Effects
Rashes, vomitting, diarrhea, long term risks of asthma, obesity and GI distress
Lower systemic burden, but limited utility
No systemic exposure
Compliance
Caregiver-managed multi-day therapy
Narrow utility for intact-barrier disease
Single-visit platform concept
OTO-101:
One Dose:
Eliminates multi-day dosing and ensures 100% treatment compliance.
No Needles:
Provides a painless, non-invasive experience.
Systemic Free:
Targets the infection locally, preventing common side effects.
Speedy Recovery:
Sterilization in 24 hours and return to daily activities for all.
Roadmap
Asset
Target Indication
Discovery
POC
Lead Opt.
IND Enable
Phase 1
Phase 2/3
OTO-101
Otology
Acute Otitis Media
OTO-102
Otology
Chronic Inflammation
OTO-201
Dermatology
Atopic Dermatitis
Platform
Respiratory & Vaccine
Delivery Application
Leadership
Built by science. Driven by translation.
Di Yang, PhD
CEO & Co-Founder
MIT-trained scientist and operating lead focused on execution, strategy, and company building.
Prof. Rong Yang, PhD
CSO & Co-Founder
Cornell biomaterials expert and scientific founder behind the platform's core discovery and translational direction.
Wenjing Tang, PhD
Chief Technology Officer
Lead discovery scientist advancing the immune-mediated delivery mechanism and formulation platform.
News
Recent News
Science Translational Medicine
Recent peer-reviewed publication validating OTO Biotech’s immune-mediated delivery concept.
OTO Biotech’s core mechanism was recently reported in Science Translational Medicine, demonstrating neutrophil-mediated delivery of antibiotics across the tympanic membrane in a preclinical model of otitis media.
View PublicationContact
Start the conversation.
Partnership, investor, and scientific inquiries.